HMGCS2 and benign neoplasm: While heterogeneity is frequently considered a significant barrier in preclinical heart HFpEF research, we contest this view and posit that Hmgcs2 is upregulated in different HFpEF animal models utilising a combined transcriptomics and proteomics analysis.